AB0199 PLACEBO AND NOCEBO RESPONSES IN RANDOMIZED CONTROLLED TRIALS OF NON-TUMOR NECROSIS FACTOR BIOLOGICS AND JANUS KINASE INHIBITORS IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS SHOWING INSUFFICIENT RESPONSE TO TUMOR NECROSIS FACTOR INHIBITORS: A META-ANALYSIS

Background: Placebo and nocebo responses have important consequences for the development of pharmaceutical drugs design randomized controlled trials (RCTs). They can lead to incorrect measurement treatment-related efficacy adverse effects (AEs). Objectives: The goal this study was evaluate frequency magnitude placebo in placebo-controlled RCTs non-tumor necrosis factor (TNF) biologics Janus kinase (JAK) inhibitors patients with rheumatoid arthritis (RA) showing an insufficient response TNF inhibitors. Methods: We performed a meta-analysis on rates response, AEs, severe AEs (SAEs), withdrawal owing clinical (RCTs) non-TNF JAK RA Results: Nine contained total 3,442 (1,840 experimental subjects 1,602 controls). pooled incidence ACR20 rate placebo-treated 22.1% (95% CI 16.4–29.1%) 27.9% 24.5–31.6%) inhibitors, respectively. A strong negative correlation observed between drug efficacies (ACR20 response) AE arm, indicating that greater weaker ( r = -0.762, P 0.017). positive active comparator, treatment 0.737, 0.003). estimate at least one 71.8% 57.4–82.7%) 58.7% 52.8–64.3%) who withdrew from 3.8% 2.7–5.3%) 4.0% 2.7–6.0%) arms, stronger arm 0.855, Conclusion: vs. RA, respectively, efficacy. References: [1]Mitsikostas DD, Chalarakis NG, Mantonakis LI, Delicha EM, Sfikakis PP. Nocebo fibromyalgia: implications practice. Eur J Neurol 2012;19:672-80. [2]Kravvariti E, Kitas GD, Mitsikostas Nocebos rheumatology: emerging concepts their Nat Rev Rheumatol 2018;14:727-40. [3]Colloca L, Barsky AJ. Effects. N Engl Med 2020;382:554-61. Disclosure Interests: None declared